- 基本信息
|
导师姓名：
|
祝宇
|
学科代码：
|
100210
|
|
|
性别：
|
男
|
学科名称：
|
外科学
|
|
培养单位：
|
附属瑞金医院
|
三级学科
|
泌尿外
|
|
导师类型：
|
博士生导师
|
专业领域名称：
|
外科学 专业学位
|
|
联系方式：
|
zyyyhyq@126.com
|
专业领域代码：
|
105111
|
|
邮编：
|
200025
|
邮箱地址：
|
zyyyhyq@126.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
浦东新区科技委员会专家库备选专家
|
|
上海市医学会泌尿外科肿瘤学组委员
|
|
现代泌尿外科杂志外审专家
|
|
上海市医学会泌尿外科分会专业委员会委员
|
|
日本泌尿器科学会会员
|
|
上海市专家会诊中心专家
|
|
上海市中西医结合学会泌尿男科专业委员会委员
|
|
JCO中文版编委
|
|
中国医师协会微无创医学专业委员会泌尿外科专业委员会副主委
|
|
上海市科学技术专家库成员
|
|
民盟上海医药专业委员会委员
|
- 科研项目
| 17ZR1417300 | 联合HSP90和HSP70双靶点治疗肾上腺恶性嗜铬细胞瘤的分子机制研究 | 上海市科学技术委员会 |
2017-05~2020-05
|
20万元
| 课题负责人 |
| 134119a2700 | 联合EGFR和IGF1R判断肾上腺皮质肿瘤良恶性的应用研究 | 上海市科学技术委员会（医学引导） |
2013-06~2016-06
|
30万元
| 课题负责人 |
| 81272936 | 双靶点抑制EGFR与IGF1-R治疗肾上腺皮质癌的分子机制研究 | 国家自然基金委员会 |
2013-01~2016-12
|
70万元
| 课题负责人 |
| 11YZ58 | Toll样受体在嗜铬细胞瘤血管内皮生长因子表达中的作用研究 | 上海市教育委员会 |
2011-01~2013-12
|
8万元
| 课题负责人 |
| 09ZR1418500 | 恶性嗜铬细胞瘤血管内皮生长因子表达的调控 | 上海市科学技术委员会 |
~
|
10万元
| 课题负责人 |
- 学术论文
|
Lin D, Wang X, Li X, Meng L, Xu F, Xu Y, Xie X, He H, Xu D, Wang C,
|
Apogossypolone acts as a metastasis inhibitor via up-regulation of E-cadherin dependent on the GSK-3/AKT complex
|
Am J Transl Res
|
2019
|
11(1):218-232
|
|
Dai J, He HC, Lin DQ,Wang CH,, Xu DF
|
Up-regulation of E-cadherin by saRNA inhibits the migration and invasion of renal carcinoma cells
|
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
|
2018
|
11(12):5792-5800
|
|
He H, Dai J, Yang X, Wang X, Sun F,
|
Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process
|
Biol Chem
|
2018
|
399(6):593-602
|
|
Lin D, Li X, Xu L, Lian J, Xu Y, Meng L, Xie X, Wang X, He H, Xu D, Wang C,
|
Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo
|
Am J Transl Res
|
2017
|
9(9):3990-4002
|
|
Meng L, Xu L, Yang Y, Zhou L, Chang Y, Shi T, Tan C, An H,, Xu J.
|
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma
|
Oncotarget.
|
2017
|
8(37):61036-61047.
|
|
Lin D, Meng L, Xu F, Lian J, Xu Y, Xie X, Wang X, He H, Wang C,
|
Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12
|
Oncol Rep
|
2017
|
38(5):3160-3166
|
|
Lian J, Lin D, Xie X, Xu Y, Xu L, Meng L,
|
NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.
|
Onco Targets Ther.
|
2017
|
10:2219-2226.
|
|
Dengqiang Lin, Yunze Xu, Lieyu Xu, Jianpo Lian,
|
Potential diagnostic and prognostic value of β-catenin and SF-1 in adrenocortical tumors
|
Int J Clin Exp Pathol
|
2017
|
10(1):401-408
|
|
Xu L, Qi Y, Xu Y, Lian J, Wang X, Ning G, Wang W,
|
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
|
Oncotarget.
|
2016
|
7(24):36235-46
|
|
Xu Y,Dong B, Huang J, Kong W, Xue W,, Zhang J, Huang Y.
|
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
|
Oncotarget.
|
2015
|
Epub ahead of print
|
|
Zhang CY,, Li K, Ian L, Ho S, Pun W, Lao H, Carvalho V, Liu DY, Shen ZJ.
|
Outcome of nephrostomy balloon dilation for vesicourethral anastomotic strictures following radical prostatectomy: A retrospective study.
|
Asian J Androl.
|
2014
|
16(1):115-9
|
|
Xu Y, Qi Y,, Ning G, Huang Y.
|
Molecular markers and targeted therapies for adrenocortical carcinoma.
|
Clin Endocrinol (Oxf).
|
2014
|
80(2):159-68.
|
|
, Xu Y, Chen D, Zhang C, Rui W, Zhao J, Zhu Q, Wu Y, Shen Z, Wang W, Ning G, Wang X.
|
Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis.
|
Clin Transl Oncol.
|
2014
|
16(7):644-9.
|
|
Xu YunZe, Qi YiCheng, Rui WenBin,
|
Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma
|
Journal of Clinical Pathology
|
2013
|
66 (4): 286-290
|
|
Xu Yunze, Rui Wenbin, Qi Yicheng,
|
The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias.
|
World journal of surgery
|
2013
|
Jul;37(7):1626-32
|
|
Zhang C, Xu Y, Chen D, Zhao J, Shen Z, Wu Y,
|
Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.
|
Tumour Biol.
|
2013
|
34(6):4065-71.
|
|
Zhao Juping,,Zhang chongyu,Wang xiaojing,He hongchao,Wang haofei
|
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinesepatients with locally advanced clear cell renal cell carcinoma at highrisk for disease recurrence
|
Urologic Oncology
|
2012
|
31(8):1800-5
|
|
Yun-Ze Xu,
|
Conventional Chemotherapy and Emerging Targeted Therapy for Advanced
Adrenocortical Carcinoma
|
Anti-Cancer Agents in Medicinal Chemistry
|
2012
|
13(2):248-253
|
|
Sheng Jy,He Hc,,Shen Zj
|
Myxoid adrenocortical tumor：report of four cases
|
Chin Med J
|
2012
|
125(9):1672-4.
|
|
Feng F,, Wang X, Wu Y, Zhou W, Jin X, Zhang R, Sun F, Kasoma Z, Shen Z.
|
Predictive factors for malignant pheochromocytoma: analysis of 136 patients
|
J Urol.
|
2011
|
185(5):1583-90.
|
|
Xu YZ,, Shen ZJ, Sheng JY, He HC, Ma G, Qi YC, Zhao JP, Wu YX, Rui WB, Wei Q, Zhou WL, Xie X, Ning G
|
Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy
|
Endocrine
|
2011
|
40(3):445-51
|
|
, He HC, Su TW, Wu YX, Wang WQ, Zhao JP, Shen Z, Zhang CY, Rui WB,ZhouWL,SunFK,NingG
|
Selective α1-adrenoceptor antagonist(controlled release tablets) in preoperative management of Pheochromocytoma.
|
Endocrine
|
2010
|
38:254-259
|
|
, He HC, Yuan F, Zhang J, Rui WB, Zhao JP, Shen ZJ, Ning G
|
Heparanase-1 and Cyclooxygenase-2:prognostic indicators of malignancy Pheochromocytomas
|
Endocrine
|
2010
|
38:93-99
|
|